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Background: Constipated patients remain dissatisfied with current treatments sug-
gesting a need for alternative therapies.
Aim: Evaluate the mechanistic effects of oral vibrating capsule in chronic idiopathic 
constipation (CIC) by examining the temporal relationships between the onset of vi-
brations,	complete	spontaneous	bowel	movements	(CSBM),	and	circadian	rhythm.
Methods: In post hoc analyses of two double-blind studies, CIC patients (Rome III) 
were	randomized	to	receive	5	active	or	sham	capsules/week	for	8	weeks.	The	cap-
sules were programmed for single vibration (study 1) or two vibration sessions with 
two modes, 8 hours apart (study 2). Daily electronic diaries assessed stool habit and 
percentage	of	CSBMs	associated	with	vibrations.	Responders	were	patients	with	≥	1	
CSBM	per	week	over	baseline.
Results: 250 patients were enrolled (active = 133, sham = 117). During and within 
3	hours	of	vibration,	there	were	significantly	more	%	CSBMs	in	the	active	vs.	sham	
group (50% vs. 42%; P	 =	 .0018).	 In	 study	2,	 there	were	 two	CSBM	peaks	 associ-
ated	with	vibration	sessions.	Significantly	more	%	CSBMs	occurred	in	active	mode	1	
(21.5%) vs. sham (11.5%); (P = .0357). Responder rates did not differ in study 1 (ac-
tive vs. sham: 26.9% vs. 35.9%, P = .19) or study 2 (mode 1 vs. sham: 50% vs. 31.8%, 




sponder rate was not different from sham. Two vibration sessions were associated 
with	more	CSBMs.
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2  | INTRODUC TION
Chronic constipation is a common gastrointestinal disorder, that is 
estimated to affect up to 27% of the population, most of whom are 
women (~75%1).	 Severe	 constipation	 (eg,	 two	bowel	movements	 a	
month) is reported almost exclusively in women. It is more prevalent 
among people of color than among white persons, and its prevalence 
increases with age.1 Chronic constipation significantly affects qual-
ity of life and is perceived by patients as a severe illness.1-3 This bur-
den is further compounded by significant direct and indirect costs, 
and for instance, chronic constipation is the sixth leading reason for 
an ambulatory clinic visit.3,4
Surveys	 show	 that	 many	 constipated	 patients	 are	 dissatisfied	
with	current	treatments;	a	US	study	showed	that	47%	of	constipated	
patients are not completely satisfied with their current constipation 
treatment,3 causing many patients to express an interest in new 
therapies.5
A	promising	avenue	for	constipation	therapy	is	direct	mechanical	
stimulation of the intestine, or dispersion of stool within a hollow 
lumen facilitating movement. Previous studies using various types of 
external vibration devices, such as a vibrating platform or an exter-
nal vibrating belt,6,7 have suggested that vibration devices may help 
constipation. Wu and colleagues tested low-intensity whole-body 
vibration induced by a noninvasive oscillation platform and found 
that it may be an effective therapy for reducing symptom severity in 
patients with chronic functional constipation compared to a control 
group of no treatment.6 The vibrating capsule, builds on these elec-
tro-mechanical	devices,	and	unlike	external	vibration,	the	vibrating	
capsule may stimulate the intestinal wall by local contact and en-
hance movement of stool, but this hypothesis merits further testing.
The vibrating capsule is a novel, miniaturized capsule device8 de-
veloped as an alternative non-pharmacological treatment modality 
for gut dysmotility. The capsule is activated by an electromagnetic 
signal and it carries an activation code produced by the base unit. 
The code includes the timing and duration of vibration for each 
capsule.
Our hypothesis was that colonic vibrations could induce satis-
factory bowel movements coinciding with colonic circadian rhythm, 
resulting in relief of constipation. This was based on a previous study 
in healthy volunteers, where we observed a significant increase in 
the	mean	number	of	bowel	movements/week	after	treatment	with	
the	vibrating	capsule	and	without	significant	adverse	effects	(AE).8 
However, its effects in patients with chronic constipation and its 
mechanism of action are unclear.
In post hoc analyses of two randomized, double-blind, sham-con-
trolled studies, we assessed the effects of the vibrating capsule on 
the frequency, timing, and circadian rhythm of bowel movements 
in patients with chronic idiopathic constipation (CIC), by examining 
the temporal relationship between activation of vibration and the 
occurrence	 of	 complete	 spontaneous	 bowel	 movements	 (CSBM).	
Additionally,	we	assessed	whether	there	was	a	dose	response,	that	
is, whether two vibration sessions per day resulted in more bowel 
movements.
3  | MATERIAL S AND METHODS
3.1 | Study design and population
Both	 studies	 were	 prospective,	 adaptive,	 multicenter,	 randomized,	
double-blind, and sham-controlled. The studies were conducted 
in	multiple	medical	centers	 in	 the	USA	between	February	2017	and	
March	2018.	Subjects	with	CIC	(Rome	III	criteria9) who self-reported 
constipation symptoms and were refractory to osmotic and stimulant 
laxatives	 for	at	 least	one	month	were	 recruited	 for	both	studies.	All	
subjects	were	adults	≥	22	years	old	who	had	between	1	and	3	sponta-
neous	bowel	movements	(SBM)	per	week.	To	be	eligible,	subjects	had	
to have a normal colonoscopy within 10 years, or be < 50 years old 
and without a family history of colorectal cancer or any alarm symp-
toms.10 Patients with any history of complicated/obstructive diverticu-
lar disease, documented/suspected intestinal obstruction, significant 
gastrointestinal disorder (including ulcerative colitis, Crohn's disease, 
gastrointestinal malignancy) or gastroparesis, patients with a history 
of	 an	 eating	 disorder,	 a	 history	 of	 Zenker's	 diverticulum,	 dysphagia,	
Barrett's	 esophagus,	 esophageal	 stricture	 or	 achalasia,	 were	 all	 ex-
cluded	from	the	study.	Subjects	with	pelvic	floor	dysfunction/defeca-
tory disorder, based on subject history such as use of digital maneuvers 
to	evacuate	or	feeling	of	anal	blockage	or	diagnosis	of	mega-rectum,	
congenital anorectal malformation and clinically significant rectocele 
were	 also	 excluded.	 Use	 of	 medications	 that	 may	 affect	 intestinal	
motility	 such	 as	 prokinetics,	 anti-Parkinsonian	medications,	 opioids,	
calcium	channel	blockers,	or	chronic	use	of	non-steroidal	anti-inflam-
matory drugs were grounds for exclusion, except antidepressants, thy-
roid or hormonal replacement therapy, and then only when on stable 
doses for at least 3 months prior to enrollment. Each subject provided 
a signed informed consent form prior to any study-related procedure. 




• Vibrating capsule is a novel non-pharmacological treat-
ment option for constipation. We assessed its effects on 
frequency, timing and circadian rhythm of bowel move-
ments and bowel symptoms in chronic constipation.
• Post-hoc analyses of two double blind sham controlled 
studies showed that during and within 3 hours of the 
onset of vibrations, a significantly greater percentage of 
complete	 spontaneous	 bowel	 movements	 (CSBM)	 oc-
curred in the active capsule group compared to the sham 
group,	 and	2	vibration	 sessions	 induced	more	CSBMs,	
although responder rates did not differ between groups.
• Vibrating capsule may improve constipation by aug-
menting	the	physiological	effects	of	waking	and	meals	
on bowel movements and circadian rhythm.




In	 both	 studies,	 there	 was	 a	 2-week	 run-in	 period	 that	 allowed	
for wash out of laxatives and other disallowed medications, and 
to gather baseline and eligibility information (see eDiary below). 
Following	 this	 period,	 at	 the	 baseline	 visit,	 subjects	 were	 rand-
omized to receive either the vibrating capsule (Vibrant®, Vibrant 
Ltd,	Hakochav	Yokneam,	Israel)	or	an	 identical	sham	capsule.	Prior	
to swallowing the capsule, the patient was instructed on how to ac-
tivate the capsule by inserting it into a base unit. This step sets and 
records the timing and duration of vibration for the capsule and cre-
ates an accurate record of compliance. The capsule includes a flat 
motor, electronic card and batteries, all encapsulated in a 2-piece 
shell, 24.2 ± 0.1 mm in length and 11.3 ± 0.1 mm in diameter.8 It 
vibrates at a frequency of 0.05 Hz (3 times/minute).
In study 1, the capsule was programmed to induce a single, in-
termittent, vibration session for approximately 2 hours that began 





In study 2, the capsule was programmed to induce two vibra-
tion sessions, each two-hours long. The first session was designed 
to	start	in	the	morning,	as	in	study	1	(around	6	AM),	and	the	second	
session started 17 hours after ingestion, approximately at noontime. 
In addition, in study 2, there were two treatment groups, each with 
a different activation mode: mode 1 included 3 vibrations/min with 
100% repetition for the entire session, and mode 2 included 3 vi-
brations/min	 and	 50%	 repetition	 for	 the	 entire	 session.	 Subjects	
received	 1	 capsule/day,	 5	 times/week.	 After	 4	weeks,	 the	weekly	
capsule	administration	regimen	was	changed	from	5	times/week	to	
2	 times/week.	This	was	done	 in	order	 to	evaluate	 the	effect	of	an	
average	of	between	2	and	5	capsules	a	week	with	multiple	vibration	
sessions.
The sham capsule was identical to the active capsule and was 
activated by using a base unit. However, after ingestion it was 
programmed not to vibrate. The regimen of administration of the 
sham capsule was identical to the active capsule for both studies. 
Study	staff	were	unaware	of	subject	active/sham	group	allocation.	
Rescue medication was allowed only after 3 consecutive days with-
out a bowel movement, and its use was documented in the eDiary. 
Patients	were	allowed	either	bisacodyl	suppository	or	Fleets	enema	
or bisacodyl 5 mg tablet per PI discretion.
F I G U R E  1  Studies	1	and	2—scheme	and	consort	flow	diagrams
(A)
(B) (C)
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3.3 | Measurements
Each subject filled out an eDiary starting with the first day of the 
run-in	 period	 and	 for	 the	 entire	 duration	 of	 8-weeks.	 The	 eDiary	
was provided to the subjects as a downloadable application for use 
on their personal mobile phones. The eDiary consisted of questions 
about bowel movements, their timing during the day and associ-
ated clinical symptoms, use of rescue medication, and use of other 








80% power at an overall 5% (2.5% for each one of the two primary 
endpoints) level of significance (two-sided) to detect a difference of 
20% in success rate (see definition below), assuming a success rate 
of 25% in the sham arm.
The sample size was increased to at least 238 subjects (119 in 
each arm) to account for a potential 10% of dropouts. Eligible sub-
jects were randomized to one of the two treatment groups based 
on	a	pre-defined	 randomization	 scheme	with	 random	size	blocks	
stratified	by	center.	For	study	2,	no	formal	sample	size	was	calcu-
lated.	A	sample	size	of	22	subjects	in	each	study	arm	was	deemed	
sufficient to achieve the trial goals. Eligible subjects were random-
ized to one of the three treatment groups based on a randomization 
scheme	 with	 fixed	 blocks	 stratified	 by	 center.	 Statistical	 anal-
yses	were	 performed	 using	 SAS®	 (SAS	 Institute,	 Cary	NC,	USA).	
Nominal P-values of two-sided statistical tests are presented. 
Baseline	 demographic	 and	 other	 baseline	 characteristics,	 as	well	





TA B L E  1  Demographics	and	Baseline	Characteristics.	It	has	been	modified	to	include	the	data	requested	by	both	reviewers











Age	(years)—mean	±	SD 45.36 ± 13.08 42.67 ± 11.15 44.39 ± 12.71 * 41.85 ± 10.70 41.3 ± 13.58
Gender
Male 18 (20.2%) 22 (23.7%) 3 (14.29%) * 4 (18.18%) 3 (12.50%)
Female 71 (79.8%) 71 (76.3%) 18 (85.71%) * 18 (81.82%) 21 (87.50%)
Body	Mass	Index—mean	±	SD 29.75 ± 6.81 28.71 ± 5.85 29.71 ± 5.32 32.57 ± 11.02 29.98 ± 9.31
Ethnicity
Caucasian 37 (41.57%) 29 (31.18%) 6 (28.57%) * 5 (22.73%) 9 (37.50%)
Hispanic	or	Latino 17 (19.10%) 22 (23.66%) 4 (19.05%) * 8 (36.36%) 6 (25.00%)
Black	or	African-American 32 (35.96%) 33 (35.48%) 10 (47.62%) * 7 (31.82%) 9 (37.50%)
Native	or	Indian	American 1 (1.12%) 4 (4.30%) 1 (4.76%) * 1(4.55%)
Asian/	Pacific	Islander 1 (1.12%) 3 (3.23%) 1(4.55%)
Other 1 (1.12%) 2 (2.15%)
Clinical Characteristics
Duration of constipation 
(years)—mean	±	SD
11.67 ± 12.46 13.09 ± 12.19 14.86 ± 10.79 8.45 ± 6.70 11.15 ± 12.33
Positive according to the 
Rome III criteria
89 (100%) 93 (100%) 22 (100%) 22 (100%) 24 (100%)
Weekly	bowel	
movements—mean	±	SD
1.93 ± 0.59 1.92 ± 0.64 1.76 ± 0.55 1.75 ± 0.38 1.99 ± 0.80
Weekly	spontaneous	bowel	
movements	–	mean	±	SD




0.45 ± 0.70 0.40 ± 0.59 0.44 ± 0.71 0.46 ± 0.74 0.55 ± 0.63
Bristol	stool	form-	mean	±	SD 2.36 ± 1.29 2.24 ± 1.13 2.18 ± 1.27 2.50 ± 1.53 2.47 ± 1.28
Straining—mean	±	SD 4.33 ± 2.30 4.77 ± 2.30 4.36 ± 2.22 4.26 ± 2.33 3.92 ± 2.07
Rescue medication use (%) 15.7% 16.3% 9.1% 9.1% 20.8%
*n = 21 
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arms. The purpose of the post hoc analyses was to understand the 
timing	of	CSBMs	across	a	24-hour	day,	and	specifically	 to	define	
the	%	of	CSBMs	occurring	during	or	 close	 to	 vibration	 cycles,	 in	
order	to	reveal	the	immediate	effect	of	vibration.	By	comparing	the	
distribution	of	CSBMs	over	time	and	in	relation	to	the	vibrations,	




Study	 1	 enrolled	 a	 total	 of	 182	 subjects,	 of	whom	89	were	 rand-
omized to receive the active capsule and 93 the sham capsule. No 
subject	 terminated	 participation	 due	 to	 an	 AE	 (Figure	 1B).	 Study	
2 enrolled a total of 68 subjects, of whom 22 were randomized to 
mode 1 active arm, 22 to mode 2 active arm, and 24 to sham arm 
(Figure	 1C).	 The	 demographic	 features	 and	 other	 baseline	 charac-
teristics were similar between the active and sham arms in both 
studies. In all groups, the mean age was between 41 and 45 years; 
the majority of subjects were females, and the ethnic distribution 
of the population was approximately equal between the two stud-
ies and active vs. sham capsules. The mean body mass index for 
all	groups	was	 in	 the	 range	defined	as	obese	 (range	of	mean	BMI:	
28.71	±	5.85-32.57	±	11.02	kg/m2), and the mean duration of con-
stipation was between 8 and 14 years. In total, 15 patients reported 
use of antidepressant drugs, 8 on active treatment, and 6 in the sham 
group (Table 1).The use of rescue medication was not significantly 
different between the groups; study 1, active vs. sham, 18.0% vs. 
13.0%; study 2, active mode 1 vs. mode 2 vs. sham, 18.2% vs. 0.0% 
vs. 12.5%, respectively.
4.2 | Effects of the vibrating capsule on CSBM and 
circadian rhythm
In	study	1,	a	higher	proportion	of	CSBMs	was	reported,	either	dur-
ing the vibration session or in up to 3 hours after the vibration time. 
Within this time window, there was a statistically significant and en-
hanced	effect	of	 the	active	capsule	compared	to	 the	sham.	About	
50%	of	the	CSBMs	reported	by	subjects	in	the	active	arm	occurred	
during or near the vibration time, compared to 42% with the sham 
capsule (P	 =	 .0018)	 (Figure	2A,	 Table	 2).	 In	 study	2,	 the	 timing	of	
the	onset	of	CSBM	showed	a	distinct	pattern	that	correlated	with	
the	 timing	 of	 the	 vibration	 sessions.	We	 observed	 two	 peaks	 for	
the	CSBMs,	each	occurring	in	close	proximity	to	the	vibration	ses-
sion	(Figure	2B),	one	in	the	morning,	upon	awakening	and	the	other	
around noon, close to mealtime. During these time intervals, fol-
lowing vibrations, the active capsule group showed a significantly 
larger	effect	on	the	onset	of	CSBMs	compared	to	the	sham	group	
(Figure	2).	Overall,	21.5%	of	the	CSBMs	reported	by	subjects	in	ac-
tive mode 1 of study 2 occurred during or near vibration time, and 
this was significantly higher when compared to the 11.5% seen in the 
sham group (P	=	.0357)	(Figure	2B).
The	 CSBM	 responder	 rates	 did	 not	 differ	 between	 the	 active	
and sham groups either in study 1 (active vs. sham: 27.9% vs. 35.9%, 
P = .1973) or in study 2 (mode 1 vs. sham: 50% vs. 31.8%, P = .2429; 
mode 2 vs. sham: 36.4% vs. 31.8% P = .7505).
4.3 | Pooled analysis
The entire population of patients treated with the active capsule 
was pooled from both studies and compared to the pooled popu-
lation of sham-treated subjects. These post hoc analyses focused 
F I G U R E  2  Correlations	between	the	timing	of	vibration	and	the	percentage	of	complete	spontaneous	bowel	movements	(CSBMs).	Time	
0	on	the	X-axis	is	the	time	of	ingestion	of	the	capsules;	black	lines	in	both	graphs	denote	the	period	of	active	vibration,	one	session	in	(A)	
study	1	and	2	sessions	in	(B)	study	2
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on the 48 hours following the administration of the last capsule 
in	 the	 study.	Again,	2	peaks	of	distribution	of	CSBMs	were	ob-
served, one occurring approximately 10-12 hours after capsule 
ingestion,	often	upon	awakening,	and	in	close	correlation	to	the	
timing of vibration, and another, at approximately 19-20 hours 
after capsule ingestion, close to the mealtime. We also observed 
a	 third	 peak	 of	 activity,	 approximately	 36	 hours	 after	 ingestion	
of	the	last	capsule,	and	this	coincided	with	the	waking	response	
on	 the	morning	 of	 the	 second	 day.	 Although	 the	 response	was	
lower than in the first morning, we observed a higher frequency 
of	CSBM	in	the	combined	vibrating	capsule	groups	compared	to	
the	combined	sham	capsule	groups.	This	additional	peak	suggests	
a residual effect of the active capsule after the last administration 
(Figure	3).
4.4 | Adverse effects





The	overall	 incidence	of	AE	was	 low,	 and	most	AE	were	mild	 and	
transient	(Table	3).	Specifically,	the	incidence	of	diarrhea	was	similar	
between the active and sham groups in both studies.
5  | DISCUSSION
Here, we assessed whether the vibrating capsule enhances the per-
centage of complete spontaneous bowel movements and its temporal 
TA B L E  2  This	shows	the	number	and	%	of	CSBMs	that	occurred	during	or	close	to	the	vibration	time	(window)	per	subject	as	well	as	the	
change	in	the	number	of	CSBMs/week	in	each	group
Study 1 Study 2
Active Sham Active (mode 1) Sham
CSBM	reported	within	or	close	to	stimulation	time	













Active Sham Active	(Pooled) Sham
Change	from	Baseline	in	mean	weekly	CSBM 1.14 ± 1.73 1.455 ± 1.91 1.22 ± 1.57 1.41 ± 1.71
P-value (t test) 0.2434 0.6386
F I G U R E  3  Frequency	of	complete	
spontaneous	bowel	movements	(CSBMs)	
following the last administration of 
capsules. Time 0 on the X-axis is the 
time	of	ingestion	of	the	capsules;	black	
horizontal line in the graph denotes the 
period of active vibration of the last 
capsule
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relationship to stool evacuation in individuals with chronic consti-
pation. In these post hoc analyses, we found significantly greater 
percentage	of	CSBMs	during	the	active	vibration	period	when	com-
pared to the sham capsule period. This observation suggests that the 
active capsule may augment the intrinsic biologic changes of colonic 
motility	that	occur	after	waking11 and after meals.12 However, based 
on the responder definition selected for these studies, overall, there 
was no significant difference in the responder rates for bowel symp-
toms, between the active and sham groups.
Here we also examined any potential effects of stimulating twice 
a day vs. once a day. In study 1, patients were administered 5 cap-
sules/week	and	each	capsule	was	programmed	for	a	single	vibration	
session whereas in study 2, patients were administered 5 capsules/
week,	and	each	capsule	was	programmed	for	2	vibration	sessions.	
The responder rates in the sham, and active arms of study 1 were 
similar. In study 2, the responder rates in both active arms tended to 
be higher than in the sham arm, but there was no difference between 
the two arms, possibly due to a type II error from the small sample 
size.	However,	in	study	2,	the	timing	of	the	onset	of	CSBMs	showed	
a distinct pattern that was associated with the timing of vibration 
sessions	in	that	two	peaks	were	observed	in	close	proximity	to	the	
vibrating sessions, one in the morning and the other in the late af-
ternoon	possibly	around	mealtime.	The	percentage	of	CSBMs	in	the	
vibrant capsule group (mode 1) was significantly higher when com-





active group had more rapid colonic transit, there was no statisti-
cally significant difference between the active and sham groups.13 
Overall, these observations suggest that multiple vibration sessions, 
timing of capsule ingestion and frequency of vibrations may each 
affect the efficacy of this treatment modality.
Healthy subjects tend to have bowel movements during the 
day,	mainly	after	waking	or	after	a	meal,	but	rarely	during	the	night.	
In a study of colonic pressure activity over 24 hours in 25 ambula-
tory healthy subjects, we have previously demonstrated a biologic 
circadian	rhythm	consisting	of	a	marked	decrease	in	colonic	pres-
sure activity at night and a significant increase in pressure activ-
ity	 following	waking	 and	 after	meals.11 In a follow-up study, we 
showed that patients with chronic slow transit constipation had 
significantly	 decreased	 colonic	 pressure	 activity	 following	 wak-
ing or meals when compared to control subjects.12	Shemerovskii	
14 studied the circadian dynamics of defecation in 341 individu-
als and showed that healthy individuals had a bowel movement 
every	 day	 in	 the	morning	 between	 6	AM	 and	 noon.	 Those	with	
irregular bowel habits had bowel movements three to four times a 
week,	with	most	bowel	movements	occurring	in	the	evening	hours	
between	8	PM	and	midnight.	Thus,	 the	human	colon	 is	naturally	
programmed	 to	empty	 in	 the	morning,	 upon	awakening	 and	 this	
biorhythm may be significantly altered in patients with chronic se-
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to moderate constipation and the circadian rhythm appears to be 




intrinsic ability to respond to environmental cues including changes 
in feeding schedule.16	 Indeed,	 clock	 genes,	 particularly	 Per2,	 are	
rhythmically expressed within the epithelial cells and myenteric 
plexus of the colon and display circadian rhythm properties17,18
Although	 there	 are	 several	 useful	 therapies	 for	 chronic	 idio-
pathic constipation including laxatives, 1,19 and newer compounds 
such as secretagogues, sometimes they may cause unpredictable 
bowel movements and/or side effects including diarrhea.20,21 We 
found that the vibrating capsule was well-tolerated in both studies 
and had an overall favorable safety profile with minor and transient 
adverse events, and no significant concerns for safety. Importantly, 
it does not seem to cause significant diarrhea or nausea.
Our studies have limitations including the exploratory nature of 
study design, the post hoc analyses, the use of multiple vibration 
paradigms, and nested within study 2, two different modes of cap-
sule	activation,	as	well	as	the	small	sample	sizes.	Further,	while	the	
subjects were well-matched with sham controls, the choice of the 
sham control may have prevented a true understanding of the mag-
nitude	of	the	vibrating	capsule's	effect.	Also,	there	was	a	withdrawal	
rate of approximately 25%-30% in both studies, possibly owing to 
patient	compliance	or	perceived	lack	of	efficacy,	but	not	due	to	any	
significant	adverse	events.	Finally,	gastrointestinal	transit	time	was	
not assessed in this study and may have provided important mech-
anistic	 insights	 regarding	 CSBM,	 circadian	 rhythm	 and	 lack	 of	 re-
sponse	from	diffuse	gastrointestinal	motility	dysfunction.	Also,	the	
relationship between vibrations and circadian rhythm may require 
evaluation by a study in which vibrations are administered at dif-
ferent	times	of	the	day.	Further,	these	observations	build	on	other	
techniques such as transabdominal interferential electrical stimula-
tion that have been shown to improve slow transit constipation.22-24
In conclusion, these post hoc analyses suggest that the vibrating cap-
sule	may	enhance	the	normal	physiologic	effects	of	waking	and	meals	on	
bowel movements, although its overall effect on bowel symptoms in con-
stipated patients was not different from that of the sham capsule. The use 
of two vibration sessions a day may additionally increase the proportion 
of	CSBMs	but	this	requires	further	studies.	These	observations	together	
with the favorable safety profile suggest that this promising technology 
may help patients with chronic constipation, but it requires confirmation 
in better designed, larger, sham, or placebo-controlled studies.
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